FDA Grants Priority Review for Bristol Myers Squibb's Camzyos in Adolescents
BMY sits 29% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb received FDA priority review for Camzyos (mavacamten) to treat adolescents with obstructive hypertrophic cardiomyopathy, with a PDUFA date set for September 30, 2026. This positive regulatory step follows strong Phase 3 results for Camzyos announced in March, accelerating its potential market expansion. The headline also notes EU approval for Opdivo with AVD for frontline classical Hodgkin lymphoma, which was previously reported yesterday. The upcoming PDUFA date for Camzyos is a key event to watch.
At the time of this announcement, BMY was trading at $55.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $112.2B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.